• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions

cafead

Administrator
Staff member
  • cafead   Feb 06, 2023 at 11:02: AM
via After a whopping $4 billion asset buy from Nimbus Therapeutics, along with a $400 million deal with Hutchmed for a colorectal cancer drug, Takeda executives touted pipeline optimism on its latest earnings call this week.

article source
 

<